ConnectiveRx Earns Top Rankings From McKinsey, Named MM+M Power Partner; Three Leaders Named to PM360 ELITE 100
ConnectiveRx Earns Top Rankings From McKinsey, Named MM+M Power Partner; Three Leaders Named to PM360 ELITE 100
Independent recognition reflects company’s leadership in patient support, client service and point-of-care engagement
ConnectiveRx, a leading provider of technology-enabled patient support and access solutions for specialty and branded medications, today announced it received top rankings in independent McKinsey research, was named an MM+M Power Partner, and had three executives named to the PM360 ELITE 100.
In independent market research conducted by McKinsey & Company, ConnectiveRx earned the highest affordability Net Promoter Score (NPS) and was also recognized as having one of the highest NPS in the patient services landscape. The assessment highlighted the company’s high level of service, robust hub, access and patient support infrastructure, automation capabilities, and strong relationships with pharmaceutical manufacturers.
The findings are reflected in ConnectiveRx’s business performance: more than 65% of the company's active hub programs began with brands transitioning from another provider, and 95% of those transitioned brands have remained long-term partners.
ConnectiveRx was also recently named an MM+M Power Partner as part of the pharmaceutical industry publication’s 2026 Agency 100 program, which highlighted the company’s leading scale in point-of-care solutions, EHR workflow integration capabilities for patient identification and provider targeting, as well as its role in reimagining what point-of-care engagement campaigns should accomplish for pharma brand marketers.
In addition, three ConnectiveRx leaders were named to the 2026 PM360 ELITE 100 in recognition of their leadership and innovation across operations, talent strategy, and commercialization:
- Sara Bowling, Vice President of Program Operations, was recognized in the Transformational Leaders category for designing best-in-class operational workflows and leading initiatives focused on real-time performance visibility for clients.
- Sandi Gray, Vice President of People Operations, was recognized in the Talent Acquisition Leaders category for transforming ConnectiveRx’s recruiting and workforce operations, including reducing average hiring timelines while improving retention and workforce scalability.
- Maria O’Mara, SVP of Business Development and Sales Operations, was recognized in the Strategist category for continuous innovation in helping pharmaceutical manufacturers develop first-to-market access and engagement programs.
About ConnectiveRx
ConnectiveRx is a leading technology-enabled pharmaceutical services company delivering patient and provider support, access, and adherence solutions for specialty and branded medications. McKinsey & Company independently ranked ConnectiveRx #1 in copay services and highest in Net Promoter Score across the patient support services landscape. The company's solutions include the industry's leading patient engagement and access platform (hub services), patient and provider adherence messaging, patient affordability programs, and the iconic Physicians' Desk Reference, now known as the Prescribers' Digital Reference. To learn more, visit connectiverx.com or follow us on LinkedIn @ConnectiveRx.
Jay Roberts, SRPR | jay@shevrushpr.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260713365388/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
2 Undervalued Stocks to Buy Before They Rebound